CoChat

Enolase-1 is a therapeutic target in endometrial carcinoma

Open access
Zhao, Mengyang, Fang, Weiyi, Wang, Yan, Guo, Suiqun, Shu, Luyun, Wang, Lijing, Chen, YiYu, Fu, Qiaofen, Liu, Yan, Hua, Shengni, Fan, Yue, Liu, Yiyi, Deng, Xiaojie, Luo, Rongcheng, Mei, Zhong, Jiang, Qinping, Liu, Zhen · 2015 · Oncotarget
Cited by 64

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// Mengyang Zhao 1, 2, * , Weiyi Fang 1, 2, * , Yan Wang 2, 5, * , Suiqun Guo 6, * , Luyun Shu 6 , Lijing Wang 2, 6 , YiYu Chen 2 , Qiaofen Fu 2 , Yan Liu 2 , Shengni Hua 2 , Yue Fan 2 , Yiyi Liu 2 , Xiaojie Deng 2 , Rongcheng Luo 1 , Zhong Mei 5 , Qinping Jiang 2, 4 , Zhen Liu 2, 3 1 Cancer Center, Traditional Chinese Medicine-Integrated Hospital of Southern Medical University, Guangzhou, Guangdong, China 2 Cancer Research Institute, Southern Medical University, Guangzhou, China 3 Department of Pathology of Basic School, Medical University of Guangzhou, Guangzhou, China 4 Department of Pathology, Third Affiliated Hospital of Guangzhou Medical College, Guangzhou, China 5 Department of Obstetrics and Gynecology of Nanfang Hospital, Southern Medical University, Guangzhou, China 6 Department of Obstetrics and Gynecology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, China * These authors have contributed equally to this work Correspondence to: Weiyi Fang, e-mail: fangweiyi1975@163.com Zhen Liu, e-mail: narcissus_jane@163.com Qingping Jiang, e-mail: 413430005@qq.com Keywords: ENO1, endometrial carcinoma, cell growth, EMT, glycolysis Received: December 30, 2014 Accepted: April 10, 2015 Published: April 24, 2015 ABSTRACT ENO1 plays a paradoxical role in driving the pathogenesis of tumors. However, the clinical significance of ENO1 expression remains unclear and its function and modulatory mechanisms have never been reported in endometrial carcinoma (EC). In this study, ENO1 silencing significantly reduced cell glycolysis, proliferation, migration, and invasion in vitro , as well as tumorigenesis and metastasis in vivo by modulating p85 suppression. This in turn mediated inactivation of PI3K/AKT signaling and its downstream signals including glycolysis, cell cycle progression, and epithelial-mesenchymal transition (EMT)-associated genes. These effects on glycolysis and cell growth were not observed after ENO1 suppression in normal human endometrial epithelial cells (HEEC). Knocking down ENO1 could significantly enhance the sensitivity of EC cells to cisplatin (DDP) and markedly inhibited the growth of EC xenografts in vivo . In clinical samples, EC tissues exhibited higher expression levels of ENO1 mRNA and protein compared with normal endometrium tissues. Patients with higher ENO1 expression had a markedly shorter overall survival than patients with low ENO1 expression. We conclude that ENO1 favors carcinogenesis, representing a potential target for gene-based therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3639

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Zhao, M., Fang, W., Wang, Y., Guo, S., Shu, L., Wang, L., Chen, Y., Fu, Q., Liu, Y., Hua, S., Fan, Y., Liu, Y., Deng, X., Luo, R., Mei, Z., Jiang, Q., & Liu, Z.
Venue
Oncotarget
Published
2015-04-24
Volume
6
Issue
17
Pages
15610-15627
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1542899887
Cited by
64
References
6
FWCI
2.45
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.